Rotavirus.

Details

• Alternative Title:
  Emerg Infect Dis
• Personal Author:
  Parashar, U. D. ; Bresee, J. S. ; Gentsch, J. R. ; Glass, R. I.
• Description:
  Rotavirus, the most common diarrheal pathogen in children worldwide, causes approximately one third of diarrhea-associated hospitalizations and 800,000 deaths per year. Because natural infection reduces the incidence and severity of subsequent episodes, rotavirus diarrhea might be controlled through vaccination. Serotypespecific immunity may play a role in protection from disease. Tetravalent rhesus-human reassortant rotavirus vaccine (RRV-TV) (which contains a rhesus rotavirus with serotype G3 specificity and reassortant rhesus-human rotaviruses with G1, G2, and G4 specificity) provides coverage against the four common serotypes of human rotavirus. In clinical trials in industrialized countries, RRV-TV conferred 49% to 68% protection against any rotavirus diarrhea and 61% to 100% protection against severe disease. This vaccine was licensed by the U.S. Food and Drug Administration on August 31, 1998, and should be cost-effective in reducing diarrheal diseases in industrialized countries. The vaccine's efficacy and cost-effectiveness in developing countries should be evaluated.
• Subjects:
  Animals Humans Research Article Rotavirus Rotavirus Infections Viral Vaccines
• Source:
  Emerg Infect Dis. 4(4):561-570.
• Document Type:
  Journal Article
• Volume:
  4
• Issue:
  4
• Collection(s):
  Emerging Infectious Diseases
• Main Document Checksum:
  urn:sha256:9a51d5628ae73267724703afb8da32f5019cc6e432c9c2405d9e147d52a7a5b4
• Download URL:
  https://stacks.cdc.gov/view/cdc/3747/cdc_3747_DS1.pdf
• File Type:
  [PDF - 356.44 KB ]